Moderna (MRNA) announces US FDA will initiate review of its investigational seasonal influenza vaccine submission; FDA assigned a prescription drug user fee act goal date of August 5th, 2026

Moderna (MRNA) announces US FDA will initiate review of its investigational seasonal influenza vaccine submission; FDA assigned a prescription drug user fee act goal date of August 5th, 2026.

Moderna's FDA submission review for its seasonal influenza vaccine is a notable development in the biotechnology space, indicating progress in diversifying its vaccine portfolio. With a PDUFA goal date set for August 5, 2026, investors should monitor not just the approval process but also how this aligns with the company's overall strategic direction and revenue potential in a competitive market.